Vaccines and Antibodies for Therapeutic Use in Cancers

This review describes briefly the beneficial use of two vaccines developedby us for treatment of cancers. The vaccine against Luteinizing Hormone ReleasingHormone (LHRH) is effective in carcinoma of prostate as well as in breast cancersdependent on androgens and estrogens respectively. LHRH being identical in bothmales and females, the same vaccine is usable in both Prostate and Breast steroidhormones-dependent-cancers. Monoclonal antibodies are finding therapeutic utilityin several cancers, and many have received Drugs Regulatory approval. The monoclonalsdeveloped by us against hCG and against epitopes present on androgen-independentcastration resistant prostate cancers are briefly recapitulated. Anti-hCG antibodieskill several cancers expressing hCG. An example is given of A549 lung carcinoma.MoAb730 and MoAb7B2G10 kill DU-145 and PC-3 androgen-independent castration resistantprostate cancer cells. Some cancers such as MOLT-4, a T-lymphoblastic leukemia,though expressing hCG are not killed by PiPP, the high affinity anti-hCG antibody.Linking the antibody to curcumin however works like a “Magic Bullet”. All MOLT-4cells are killed by this conjugate, the antibody homes selectively to cancer cellsexpressing hCG to deliver curcumin which exercises the killing effect. A recombinantvaccine, hCGβ-LTB (human chorionic gonadotropinsubunit β linked to B subunit of heat-labileenterotoxin of E. coli) has been made,which induces high titre bioeffective antibodies not only in BalbC, but also inother genetic strains of mice. The vaccine employs autoclaved Mycobacterium indicus pranii (MiP) as adjuvant.MiP invigorates both humoral and cell mediated immune responses against Human chorionicgonadotropin (hCG). Besides being a potent adjuvant, MiP used alone heals anogenitalwarts in humans and has the property of preventing and curing SP2/O Myelomas inmice.